We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Drugmakers are only urged — not obligated — to remove error-prone medical abbreviations from labeling, advertising and packaging under the FDA’s new campaign to purge these abbreviations from all forms of medical communication.
Larry Blankstein, senior director of Clinical Research at Genzyme and chairman of the clinical research track for the upcoming Drug Information Association’s (DIA) annual meeting, shared his opinions with CTA about current trends in clinical trials.
Sodium phosphate products used to prepare patients for colonoscopies can cause kidney failure, according to the consumer advocacy group Public Citizen.
Congress should pass legislation that would encourage the creation of new antibiotics to fight drug-resistant germs, according to an article in the current issue of Clinical Infectious Diseases.
An NIH study of patients who were treated with Biogen Idec and Elan’s multiple-sclerosis drug Tysabri found no new cases of progressive multifocal leukoencephalopathy (PML), a rare and deadly nerve disease that has been linked to the drug.
The New England Journal of Medicine has reiterated its December editorial detailing concerns about a Merck study of Vioxx — only the third such editorial issued by the journal since 1991, an NEJM spokeswoman told DID.
The combined use of two dietary supplements — glucosamine HCl and chondroitin sulfate — effectively relieves moderate to severe osteoarthritis pain better than celecoxib, according to an NIH-sponsored study published in the New England Journal of Medicine (NEJM).
AstraZeneca withdrew its blood thinner Exanta from overseas markets and terminated the drug’s development after studies found the product may cause severe liver damage.